866-997-4948(US-Canada Toll Free)

Binge Eating Disorder - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Diseases & Conditions

No. of Pages : 56 Pages

Binge Eating Disorder - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H1 2017, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 1 and 4 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Binge Eating Disorder - Overview
Binge Eating Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Binge Eating Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Binge Eating Disorder - Companies Involved in Therapeutics Development
Chronos Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Heptares Therapeutics Ltd
Highland Therapeutics Inc
Omeros Corp
Opiant Pharmaceuticals Inc
Shire Plc
Sunovion Pharmaceuticals Inc
Binge Eating Disorder - Drug Profiles
amphetamine MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasotraline hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lisdexamfetamine dimesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Binge Eating Disorder - Dormant Projects
Binge Eating Disorder - Discontinued Products
Binge Eating Disorder - Product Development Milestones
Featured News & Press Releases
Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
Oct 25, 2016: First And Only Medication Approved In Canada For The Treatment Of Binge Eating Disorder
Oct 17, 2016: Shire Announces Update to Vyvanse (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder
Oct 06, 2016: Study Finds New Approach to Block Binge Eating
Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets
Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
Jul 22, 2015: Vyvanse (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Moderate to Severe Binge Eating Disorder
Jun 13, 2015: PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate
May 11, 2015: Shire to Present New Research at American Psychiatric Association Annual Meeting
Jan 30, 2015: Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder
Sep 15, 2014: Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) for Adults with Binge Eating Disorder
Nov 05, 2013: Positive Top-line Results Shown for Vyvanse Capsules in Adults with Binge Eating Disorder
May 17, 2013: Shire To Present Scientific Data On Vyvanse At 166th APA Annual Meeting 2013
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Binge Eating Disorder, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, H1 2017
Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Binge Eating Disorder - Pipeline by Heptares Therapeutics Ltd, H1 2017
Binge Eating Disorder - Pipeline by Highland Therapeutics Inc, H1 2017
Binge Eating Disorder - Pipeline by Omeros Corp, H1 2017
Binge Eating Disorder - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
Binge Eating Disorder - Pipeline by Shire Plc, H1 2017
Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
Binge Eating Disorder - Dormant Projects, H1 2017
Binge Eating Disorder - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Binge Eating Disorder, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *